Project information | Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463] | Guidance

Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions

Following on from information provided to NICE by the company in June 2012, the appraisal of Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

Status	Discontinued
Technology type	Medicine
Decision	Selected
Process	TA
ID number	463
Referral date	01 May 2011
Topic area	Cardiovascular

Provisional Schedule

Closing date for invited submissions / evidence submission:	TBC
1st appraisal committee meeting:	TBC

Project Team

Communications manager:	TBC
Executive Lead:	TBC
Project manager:	Bijal Joshi
Technical Lead:	TBC

Email enquiries

If you have any queries please email scheduling@nice.org.uk

Timeline

Key events during the development of the guidance:

Date	Update
09 November 2022	Discontinued. Following on from information provided to NICE by the company in June 2012, the appraisal of Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
8 June 2012	The Institute has now been informed by the manufacturer that it is not currently pursuing a licensing application for rivaroxaban in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme for the time being. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
25 August 2011	As you are aware, the Department of Health has asked us to carry out a single technology appraisal of rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions. Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established. The deadline for evidence submission, which was 3 October 2011, no longer applies in this instance.

Date

Update

09 November 2022

Discontinued. Following on from information provided to NICE by the company in June 2012, the appraisal of Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

8 June 2012

The Institute has now been informed by the manufacturer that it is not currently pursuing a licensing application for rivaroxaban in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

25 August 2011

As you are aware, the Department of Health has asked us to carry out a single technology appraisal of rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions.

Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.

The deadline for evidence submission, which was 3 October 2011, no longer applies in this instance.

For further information on our processes and methods, please see our CHTE processes and methods manual